Does Antipsychotic Dose Reduction Lead To Better Functional Recovery In First Episode Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,371,552.00
Summary
Can a person with a first episode of psychosis, once remitted, reduce their dosage of medication and still achieve better outcomes in functioning, physical health and brain volume, than if they had stayed on traditional maintenance doses of medication? This study will examine if using a dose reduction strategy in conjunction with an evidence based suite of psychosocial interventions leads to better social and vocational recovery and improved physical health and brain volume.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.
Connecting The Dots: Novel Social Media Technologies For Long-term Functional Recovery In First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$432,528.00
Summary
The aim of this program of research is to evaluate the effectiveness of innovative online social media and mobile-based interventions purposely designed to improve long-term recovery in youth mental health (i.e., early psychosis and youth depression). These pioneering interventions have been designed by a large multidisciplinary team through the integration of cutting-edge social media technologies, new psychological models and strong consumer-youth participation.
A Comparison Of An Integrated Psychological Intervention With 'befriending' In First-presentation Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$356,113.00
Summary
The project aims to test the efficacy of two treatments to determine whether 'integrated' psychological treatment leads to better outcomes for those individuals presenting for treatment for the first time. Neuroleptic medication is the main treatment for the positive symptoms (i.e., delusions, hallucinations and thought disorder) which typify the psychoses, including schizophrenia. Yet, there are reasons why other approaches should be investigated. Firstly, not all patients respond to medication ....The project aims to test the efficacy of two treatments to determine whether 'integrated' psychological treatment leads to better outcomes for those individuals presenting for treatment for the first time. Neuroleptic medication is the main treatment for the positive symptoms (i.e., delusions, hallucinations and thought disorder) which typify the psychoses, including schizophrenia. Yet, there are reasons why other approaches should be investigated. Firstly, not all patients respond to medications. Secondly, medication may not totally alleviate the positive symptoms, and thirdly, other aspects of the condition are not helped to any extent by medication. These aspects include negative symptoms (e.g., lack of motivation and asociality), depression, social anxiety and functioning in the various life domains, e.g., school, work and socialization. In the last 15 years a viable psychological treatment known as cognitive-behavioural therapy (CBT) has emerged. This appears to be effective in the treatment of hallucinations and delusions and has an effect over and above that produced by medication. However, such treatments have not yet been applied to treating those symptoms in first presentation psychotic patients when they are in the acute stage of their illness. It is important to determine whether CBT produces positive effects in this group and whether used in conjunction with medication it can produce greater and more rapid reductions in the level and severity of positive symptoms. Whilst CBT is expected to produce positive changes in delusions and hallucinations, the applicants believe this needs to be integrated with CBT interevention focussed on other aspects of a patient's presentation, such as negative and depressive symptoms, and also on improving functioning in various life domains.Read moreRead less
Randomised Controlled Trial Of Cognitive Behaviour Therapy To Prevent Psychosis Among People With At-risk Mental States.
Funder
National Health and Medical Research Council
Funding Amount
$619,604.00
Summary
Recent advances in the accurate identification of individuals at high risk of developing a psychotic disorder, such as schizophrenia, have inspired the development of interventions designed to delay, ameliorate or even prevent the onset of such disorders. To date, the results of only three randomised controlled trials of such interventions have been published. Although these results have shown that interventions are able to delay the onset of psychosis, and may even prevent psychosis in some cas ....Recent advances in the accurate identification of individuals at high risk of developing a psychotic disorder, such as schizophrenia, have inspired the development of interventions designed to delay, ameliorate or even prevent the onset of such disorders. To date, the results of only three randomised controlled trials of such interventions have been published. Although these results have shown that interventions are able to delay the onset of psychosis, and may even prevent psychosis in some cases, it is unclear which treatment should be preferred for this population because the three trials have assessed, respectively, a combination of anti-psychotic medication and cognitive behaviour therapy (CBT), CBT alone, and anti-psychotic medication alone. Since the trial of CBT alone produced results that were at least as favourable as the two other trials, and since ethical and clinical objections have been raised concerning the use of anti-psychotic medications with young people who may never develop a psychotic disorder, CBT may be the preferred treatment. Far from posing unnecessary risks, CBT has the potential to provide important therapeutic benefits even to those not destined to develop a psychosis. The current study is significant in that it proposes a controlled trial of a form of CBT which has been specially adapted for preventing transition to psychosis among young high-risk individuals, to test whether the previous favourable results for CBT can be independently replicated. It will be compared with a control treatment. Since cannabis abuse is common among young people who are at risk, and is a known risk factor for psychosis, CBT will include elements of treatment for cannabis abuse. The trial will be run in both Newcastle and Orange, NSW, enabling us to compare the effectiveness of CBT in urban and rural settings. This study has the potential to have large impacts on the quality of life of young people at risk of psychosis.Read moreRead less
GEM Study: General And Emotional Cognition In First Onset Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$385,659.00
Summary
Schizophrenia is a devastating mental illness that disrupts cognitive and emotional function. We assessed which cognitive and emotional impairments characterize the first onset of schizophrenia and identified their brain basis in neural circuits. We also assessed whether these impairments predict outcomes over time.
A Prospective Study Investigating Implications Of Bioactive Lipids For Diagnosis And Treatment Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$324,480.00
Summary
This study will investigate the role of fatty acids (lipids) in schizophrenia. Studies in blood cells and in the brains of patients with schizophrenia have shown that these lipids and related products are altered in schizophrenia. We are now able to measure separate lipid metabolites in the living human brain using a technique called magnetic resonance spectroscopy. Until recently it was only possible to assess lipid metabolites as a group, limiting interpretation. Thanks to a newly available im ....This study will investigate the role of fatty acids (lipids) in schizophrenia. Studies in blood cells and in the brains of patients with schizophrenia have shown that these lipids and related products are altered in schizophrenia. We are now able to measure separate lipid metabolites in the living human brain using a technique called magnetic resonance spectroscopy. Until recently it was only possible to assess lipid metabolites as a group, limiting interpretation. Thanks to a newly available imaging system at the Brain Imaging Research Institute and a new analysis technique, we will be able to measure single lipid metabolites in the living human brain. Simultaneously we will also measure lipids and related enzymes in red blood cells that are responsible for the regulation of these lipids. Preliminary data has shown that there is a strong correlation between these two measures. Furthermore we will investigate the genes that are responsible for the production of these enzymes. By repeating the same tests after 12 weeks we hope to understand how the newer antipsychotic drugs act. Two easy clinical tests (a skin and breath test) will help us to implement the findings in daily clinical practice (diagnostic markers for patients at risk) . With such a multi-level approach we hope to contribute to a new understanding of the origins of schizophrenia going beyond the traditional concepts. The findings might also have direct implications for treatment. Preliminary results are very promising but also contradictory. Therefore it is even more important to carefully investigate the role of these lipids in schizophrenia.Read moreRead less